Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $8.50

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $8.50.

ANRO has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Alto Neuroscience in a research note on Thursday. Wedbush restated a "neutral" rating and issued a $4.00 price target on shares of Alto Neuroscience in a research note on Thursday, May 15th. Finally, William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its stake in Alto Neuroscience by 63.7% during the fourth quarter. Bank of America Corp DE now owns 56,532 shares of the company's stock valued at $239,000 after buying an additional 22,007 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Alto Neuroscience by 198.1% during the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company's stock worth $2,484,000 after acquiring an additional 390,190 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Alto Neuroscience by 885.4% during the 4th quarter. BNP Paribas Financial Markets now owns 42,520 shares of the company's stock worth $180,000 after acquiring an additional 38,205 shares in the last quarter. Cantor Fitzgerald L. P. bought a new position in shares of Alto Neuroscience during the 4th quarter valued at approximately $1,575,000. Finally, Jane Street Group LLC grew its holdings in shares of Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock valued at $79,000 after purchasing an additional 7,783 shares in the last quarter.

Alto Neuroscience Stock Performance

NYSE ANRO traded down $0.10 on Friday, reaching $2.21. 390,164 shares of the stock were exchanged, compared to its average volume of 408,834. The firm has a market capitalization of $59.83 million, a PE ratio of -0.94 and a beta of 1.93. Alto Neuroscience has a one year low of $1.60 and a one year high of $17.55. The company's 50-day simple moving average is $2.47 and its two-hundred day simple moving average is $3.08. The company has a current ratio of 22.53, a quick ratio of 22.53 and a debt-to-equity ratio of 0.15.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.06. Analysts expect that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.